FDA approves Ionis’ RNA-targeting therapy to treat rare disease that causes swelling attacks

The FDA approved Ionis’ rare disease medicine donidalorsen and the company hopes to convince a majority of patients who use differing prophylactic and on-demand treatments to use its drug. Ionis said Thursday that donidalorsen, which ...